New Enterprise Associates 16, L.P.

Filings by New Enterprise Associates 16, L.P. span 7 companies, the busiest being Trevi Therapeutics, Inc., Metacrine, Inc. and Akouos, Inc. The record holds 33 filings, for trades running from 14 February 2019 to 2 October 2025.

Market trades split into 12 purchases (€79.4M) and 7 sales (€1.1M). No amount is published for 1 filing, which the totals therefore leave out. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 3 share grants and 1 option exercise. In 2025 alone, the filings show no purchases and 1 sale.

A typical purchase (the median) is worth €8.4M. 7 out of 9 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. After 5 purchases with a full 90-day history, the hit rate stands at 20% and the median 90-day move at -44.9%. This is a record of the past, not a forecast.

Most recently, on 6 October 2025, the filings show a transaction in NeueHealth, Inc. The last insider purchase was made public on 23 December 2024, 670 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.